Vijoice (Alpelisib) Patent Expiration, LOE Window & CMS Spending

Vijoice (Alpelisib) by Novartis: FDA Orange Book core substance LOE 2033-04-29 (last listed 2037-02-17), 0 AB generics, $90.9M 2024 CMS Part D & Medicaid spend, and $32,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN215039 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-04-29
Last Listed Patent or Exclusivity Date2037-02-17
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$90.9M
2024 Medicare Part D Spend$8.5M
2024 Medicaid Spend$82.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($32,500 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.